Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Blood tumor mutational burden: are we ready for clinical implementation?

Literature DB >> 31632782

Blood tumor mutational burden: are we ready for clinical implementation?

Claude Van Campenhout¹, Bárbara Meléndez¹, Myriam Remmelink¹, Isabelle Salmon¹, Nicky D'Haene¹.

Abstract

Entities: Chemical

Year: 2019 PMID： 31632782 PMCID： PMC6783780 DOI： 10.21037/jtd.2019.07.60

Source DB: PubMed Journal: J Thorac Dis ISSN： 2072-1439 Impact factor: 2.895

× No keyword cloud information.

13 in total

1. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors: Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal: N Engl J Med Date: 2018-04-16 Impact factor: 91.245

2. Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors: Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal: N Engl J Med Date: 2014-11-19 Impact factor: 91.245

3. Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?

Authors: Conor E Steuer; Suresh S Ramalingam
Journal: J Clin Oncol Date: 2018-01-16 Impact factor: 44.544

4. Pembrolizumab for the treatment of non-small-cell lung cancer.

Authors: Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi
Journal: N Engl J Med Date: 2015-04-19 Impact factor: 91.245

5. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer.

Authors: C Lim; M S Tsao; L W Le; F A Shepherd; R Feld; R L Burkes; G Liu; S Kamel-Reid; D Hwang; J Tanguay; G da Cunha Santos; N B Leighl
Journal: Ann Oncol Date: 2015-04-28 Impact factor: 32.976

6. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors: Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245

7. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors: Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal: Science Date: 2015-03-12 Impact factor: 47.728

8. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.

Authors: Zhijie Wang; Jianchun Duan; Shangli Cai; Miao Han; Hua Dong; Jun Zhao; Bo Zhu; Shuhang Wang; Minglei Zhuo; Jianguo Sun; Qiming Wang; Hua Bai; Jiefei Han; Yanhua Tian; Jing Lu; Tongfu Xu; Xiaochen Zhao; Guoqiang Wang; Xinkai Cao; Fugen Li; Dalei Wang; Yuejun Chen; Yuezong Bai; Jing Zhao; Zhengyi Zhao; Yuzi Zhang; Lei Xiong; Jie He; Shugeng Gao; Jie Wang
Journal: JAMA Oncol Date: 2019-05-01 Impact factor: 31.777

9. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.

Authors: Eliezer M Van Allen; Nikhil Wagle; Petar Stojanov; Danielle L Perrin; Kristian Cibulskis; Sara Marlow; Judit Jane-Valbuena; Dennis C Friedrich; Gregory Kryukov; Scott L Carter; Aaron McKenna; Andrey Sivachenko; Mara Rosenberg; Adam Kiezun; Douglas Voet; Michael Lawrence; Lee T Lichtenstein; Jeff G Gentry; Franklin W Huang; Jennifer Fostel; Deborah Farlow; David Barbie; Leena Gandhi; Eric S Lander; Stacy W Gray; Steven Joffe; Pasi Janne; Judy Garber; Laura MacConaill; Neal Lindeman; Barrett Rollins; Philip Kantoff; Sheila A Fisher; Stacey Gabriel; Gad Getz; Levi A Garraway
Journal: Nat Med Date: 2014-05-18 Impact factor: 53.440